试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-27
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
编号:NCT04390152登记状态:提前终止企业 / 申办者:BioXcellerator
药物 / 成分:Wharton's jelly derived Mesenchymal stem cells.、Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
登记的停止原因(原文):Stopped by the IP, because the first 6 patients recruited had died and it was unknown if it represented any safety risk or if the sample was insufficient to evaluate the study hypotesis.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-27
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
编号:NCT04934670登记状态:提前终止企业 / 申办者:Xenikos
药物 / 成分:T-Guard、Ruxolitinib
登记的停止原因(原文):The study met the protocol defined stopping boundary for Day 60 mortality when comparing mortality between the T-Guard and ruxolitinib arms
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-26
Sitravatinib in Metastatic Breast Cancer
编号:NCT04123704登记状态:提前终止企业 / 申办者:Xiang Zhang
药物 / 成分:Sitravatinib
登记的停止原因(原文):Terminated by sponsor due to lack of interest
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-26
Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
编号:NCT04632940登记状态:提前终止企业 / 申办者:Kyntra Bio
药物 / 成分:Pamrevlumab、Placebo、Corticosteroids
登记的停止原因(原文):Study did not meet its primary endpoint.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-26
Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology
编号:NCT04722809登记状态:提前终止企业 / 申办者:Centre Hospitalier Universitaire Dijon
药物 / 成分:Botulinum toxin injection、QOL-Brux、Muscular strength of the jaw、Intensity and frequency of episodes of nocturnal bruxism
登记的停止原因(原文):Difficulties in recruiting patients, compounded by problems extracting data from the device used in the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-23
Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis
编号:NCT00517868登记状态:提前终止企业 / 申办者:Urigen
药物 / 成分:URG101、Placebo
登记的停止原因(原文):The study was terminated due to Food and Drug Administration (FDA) recalled the heparin used in the trial because of possible contamination.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-23
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
编号:NCT00791154登记状态:提前终止企业 / 申办者:NantCell, Inc.
药物 / 成分:AMG 479、Etoposide、Placebo、AMG 102
登记的停止原因(原文):Subjects discontinued study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-23
Enhanced Recovery Strategies in Elective Breast Surgery
编号:NCT03187080登记状态:提前终止企业 / 申办者:University of Wisconsin, Madison
药物 / 成分:Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline、Enhanced recovery after breast surgery (ERABS) strategies、Sham paravertebral block using saline、Paravertebral block using local anesthetic
登记的停止原因(原文):per Research Hold
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-23
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
编号:NCT03486327登记状态:提前终止企业 / 申办者:Bracco Diagnostics, Inc
药物 / 成分:BR55
登记的停止原因(原文):Sponsor decision; expiration of available study agent due to long recruitment timeline.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-23
Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality
编号:NCT03594175登记状态:提前终止企业 / 申办者:Chiesi Farmaceutici S.p.A.
药物 / 成分:CUSA-081、Placebo、Alteplase
登记的停止原因(原文):Due to ongoing recruitment challenges globally, it is not possible to complete this study. The decision is not based on any reported changes in the safety profile or any concerns with the anticipated efficacy profile of the investigational product.
查看官方原始记录 ↗